drugset / Trial / NCT04503668
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
RandomizedParallel-groupOpen-labelSupportive care
Summary
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.
Timeline
- Start
- 2020-12-28
- Primary completion
- 2024-01-03
- Completion
- 2024-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fosaprepitant | Other / unclassified | 150 mg | Intravenous |
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Background | Ondansetron | Other / unclassified | 8 mg | Intravenous |
| Background | Prochlorperazine | Small molecule | 5 mg | Oral |
| Background | Prochlorperazine | Small molecule | 10 mg | Oral |